Drug repurposing or re-profiling has been the hallmark to bring strong business growth and the trend is being followed by majority of the pharmaceutical and biopharmaceutical companies. Among all biologics approved in the U.S. during 2007-2009, 30-40% of them were the drugs repurposed or repositioned. National Institute of Health (NIH), U.S. Department of Health defines drug repurposing as discovering new uses for approved drugs to provide the quickest possible transition from bench to bedside. Drug repurposing opens up various opportunities to answer current unmet medical needs to come up with cost-effective solutions to expensive drug development process. Repurposing or re-profiling of drugs which are suspended due to lack of efficacy or specificity can be a good start over for further development for new indication. Finding new indications for already studied drugs can benefit patients by getting quick access to new treatment choices and also to developer by saving time and money while maintaining its original IP protection. For many expensive indications such as cancer, scrutinizing for anti-cancer activity among dozens of off-patent drugs that have already established their safety is a powerful method opted by majority of the big pharma companies. However, repurposing is not a new strategy and there are bunch of drugs which are repositioned or repurposed, some of them are Raloxifene (approved for treatment of osteoporosis in 2007, originally indicated for breast cancer treatment), Thalidomide (repositioned for use in treatment of leprosy and multiple myeloma in 2006), Rapamycin (repurposed in 1999 for prevention of organ transplant rejection), Sildenafil (originally approved for erectile dysfunction and recently got approved for treatment of angina) and many others.
Requirement of low investment of time and money in the drug development is the prime advantage of drug repurposing and majority of the drugs in pipeline of major pharmaceutical companies are thus adopt this method. Some of the factors accelerating the drug repurposing activities include sunk research cost, ready availably of bioavailability, pharmacology, toxicity profile & pharmacokinetics data, well established manufacturing protocol etc.; which are expected to drive the global drug repurposing market. There are thousands of failed molecules shelved into the drug libraries, which hold vast potential to reposition. Whereas, limited access chemical structure data of drug molecules, lack of funding etc. are some of the factors limiting the growth of global drug repurposing market.
Access Report Details at: https://www.themarketreports.com/report/global-drug-repurposing-market-research-report
The global Drug Repurposing market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Drug Repurposing volume and value at global level, regional level and company level. From a global perspective, this report represents overall Drug Repurposing market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
Key companies profiled in Drug Repurposing Market report are Astellas Pharma, Biovista, Novartis, Abbvie, Pfizer, Allergan and more in term of company basic information, Product Introduction, Application, Specification, Production, Revenue, Price and Gross Margin (2014-2019), etc.
Purchase this Premium Report at: https://www.themarketreports.com/report/buy-now/1429462
Table of Content
1 Drug Repurposing Market Overview
2 Global Drug Repurposing Market Competition by Manufacturers
3 Global Drug Repurposing Production Market Share by Regions
4 Global Drug Repurposing Consumption by Regions
5 Global Drug Repurposing Production, Revenue, Price Trend by Type
6 Global Drug Repurposing Market Analysis by Applications
7 Company Profiles and Key Figures in Drug Repurposing Business
8 Drug Repurposing Manufacturing Cost Analysis
9 Marketing Channel, Distributors and Customers
10 Market Dynamics
11 Global Drug Repurposing Market Forecast
12 Research Findings and Conclusion
13 Methodology and Data Source